Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Waldenstrom Macroglobulinemia 1 Small Cell Lung Carcinoma 1 Sezary Syndrome 1 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Neoplasms 1 Mycosis Fungoides 1 Malignant Disease 1 Lymphoma, T-Cell, Cutaneous 1 Lymphoma, Non-Hodgkin 1 Lymphoma, Mantle-Cell 1 Lymphoma, Large-Cell, Immunoblastic 1 Lymphoma, Large-Cell, Anaplastic 1 Lymphoma, Large B-Cell, Diffuse 1 Lymphoma, Follicular 1 Lymphoma, B-Cell, Marginal Zone 1 Lymphoma 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Intraocular Lymphoma 1 Immunoblastic Lymphadenopathy 1 Hodgkin Disease 1 Burkitt Lymphoma 1

Interventions

Etoposide 154 Carboplatin 142 Cisplatin 104 Topotecan 74 durvalumab 48 atezolizumab 46 Irinotecan 44 pembrolizumab 39 Paclitaxel 34 Nivolumab 33 Radiotherapy 29 anlotinib 23 PM 01183 22 Gemcitabine 21 Drug Therapy 20 apatinib 19 Ipilimumab 18 Docetaxel 17 Temozolomide 16 Platinum 16 Radiosurgery 15 Pemetrexed 14 toripalimab 13 tislelizumab 13 olaparib 13 Bevacizumab 13 amrubicin 11 Magnetic Resonance Spectroscopy 11 Cyclophosphamide 11 rovalpituzumab tesirine 10

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Small Cell Lung Carcinoma × amuvatinib × Clear all

NCT01357395 2024-08-02

ESCAPE

Astex Pharmaceuticals, Inc.

Phase 2 Completed

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡